bioRxiv Science⌕ Search

Biology subjects

Shen, R.

Publications and source records attributed to Shen, R..

39 records · Page 3Linked to original sources

Predicting the Genomic Resolution of Bulk Segregant Analysis

Bulk segregant analysis (BSA) is a technique for identifying the genetic loci that underlie phenotypic trait differences. The basic approach of this method is to compare two pools of individuals from the opposing tails of the phenotypic distribution, sampled from an interbred population. Each pool is sequenced and scanned for alleles that show divergent frequencies between the pools, indicating potential association with the observed trait differences. BSA has already been successfully applied to the mapping of various quantitative trait loci in organisms ranging from yeast to maize. However, these studies have typically suffered from rather low mapping resolution, and we still lack a detailed understanding of how this resolution is affected by experimental parameters. Here, we use coalescence theory to calculate the expected genomic resolution of BSA. We first show that in an idealized interbreeding population of infinite size, the expected length of the mapped region is inversely proportional to the recombination rate, the number of generations of interbreeding, and the number of genomes sampled, as intuitively expected. In a finite population, coalescence events in the genealogy of the sample reduce the number of potentially informative recombination events during interbreeding, thereby increasing the length of the mapped region. This is incorporated into our theory by an effective population size parameter that specifies the pairwise coalescence rate of the interbreeding population. The mapping resolution predicted by our theory closely matches numerical simulations. Furthermore, we show that the approach can easily be extended to modifications of the crossing scheme. Our framework enables researchers to predict the expected power of their mapping experiments, and to evaluate how their experimental design could be tuned to optimize mapping resolution.

genetics↗

Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering

Molecular phenotypes of cancer are complex and influenced by a multitude of factors. Conventional unsupervised clustering of heterogeneous cancer patient populations is inevitably driven by the dominant variation from major factors such as cell-of-origin or histology. Drawing from ideas in supervised text classification, we developed survClust, an outcome-weighted clustering algorithm for integrative patient stratification. We show survClust outperforms unsupervised clustering in identifying cancer patient subpopulations characterized by specific genomic phenotypes with more aggressive clinical behavior. The algorithm and tools we developed have direct utility toward clinically relevant patient stratification based on tumor genomics to inform clinical decision-making.

genomics↗

Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases

Three anti-HIV drugs, ritonavir, lopinavir and darunavir, might have therapeutic effect on coronavirus disease 2019 (COVID-19). In this study, the structure models of two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteases, coronavirus endopeptidase C30 (CEP_C30) and papain like viral protease (PLVP), were built by homology modeling. Ritonavir, lopinavir and darunavir were then docked to the models, respectively, followed by energy minimization of the protease-drug complexes. In the simulations, ritonavir can bind to CEP_C30 most suitably, and induce significant conformation changes of CEP_C30; lopinavir can also bind to CEP_C30 suitably, and induce significant conformation changes of CEP_C30; darunavir can bind to PLVP suitably with slight conformation changes of PLVP. It is suggested that the therapeutic effect of ritonavir and lopinavir on COVID-19 may be mainly due to their inhibitory effect on CEP_C30, while ritonavir may have stronger efficacy; the inhibitory effect of darunavir on SARS-CoV-2 and its potential therapeutic effect may be mainly due to its inhibitory effect on PLVP.

biochemistry↗